These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19616706)

  • 21. Antiretroviral update: further validation of the guidelines.
    Boyle BA
    AIDS Read; 2006 Feb; 16(2):83-6. PubMed ID: 16471274
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiretroviral treatment French guidelines 2013: economics influencing science.
    Raffi F; Reynes J
    J Antimicrob Chemother; 2014 May; 69(5):1158-61. PubMed ID: 24443513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ART for children: what to start and when to switch.
    Sutcliffe CG; Moss WJ
    Lancet Infect Dis; 2011 Apr; 11(4):254-5. PubMed ID: 21288775
    [No Abstract]   [Full Text] [Related]  

  • 24. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
    Bélec L; Bonn JP
    Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy for children in the routine setting in Malawi.
    Malawi Paediatric Antiretroviral Treatment Group
    Trans R Soc Trop Med Hyg; 2007 May; 101(5):511-6. PubMed ID: 17197006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
    Kent DM; McGrath D; Ioannidis JP; Bennish ML
    Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
    Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
    Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Balancing effectiveness and access to HIV treatment in the developing world.
    Hill A; Wood E
    AIDS; 2007 Jan; 21(3):361-3. PubMed ID: 17255743
    [No Abstract]   [Full Text] [Related]  

  • 29. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory monitoring of HIV/AIDS in a resource-poor setting.
    Glencross DK; Mendelow BV; Stevens WS
    S Afr Med J; 2003 Apr; 93(4):262-3. PubMed ID: 12806710
    [No Abstract]   [Full Text] [Related]  

  • 31. [Epidemiology of HIV. Update].
    Dorrucci M
    Recenti Prog Med; 2010 Jan; 101(1):12-5. PubMed ID: 20391681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Access to HIV drugs: are we changing the two world paradigm?
    Lazzarini Z
    Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
    [No Abstract]   [Full Text] [Related]  

  • 33. National adult antiretroviral therapy guidelines in South Africa: concordance with 2003 WHO guidelines?
    Lawn SD; Wood R
    AIDS; 2007 Jan; 21(1):121-2. PubMed ID: 17148984
    [No Abstract]   [Full Text] [Related]  

  • 34. WHO guidelines for antiretroviral therapy in serodiscordant couples in sub-Saharan Africa: how many fit?
    Kouamé G; Danel C; Moh R; Badjé A; Jean K; N'takpe JB; Gabillard D; Le Carrou J; du Loû AD; Deschamps N; Eholie S; Anglaret X
    AIDS; 2014 Jun; 28(10):1533-5. PubMed ID: 24804862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV meds: keeping trouble at bay.
    Daughtry LM; Bankston JB; Deshotels JM
    RN; 2002 Feb; 65(2):31-5; quiz 36. PubMed ID: 15328865
    [No Abstract]   [Full Text] [Related]  

  • 37. [Highly active antiretroviral therapy--update 2008].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():4-7. PubMed ID: 19031559
    [No Abstract]   [Full Text] [Related]  

  • 38. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common adverse effects of antiretroviral therapy for HIV disease.
    Reust CE
    Am Fam Physician; 2011 Jun; 83(12):1443-51. PubMed ID: 21671545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.
    Bennett DE; Bertagnolio S; Sutherland D; Gilks CF
    Antivir Ther; 2008; 13 Suppl 2():1-13. PubMed ID: 18578063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.